NCT05704244 - Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 21, 2022

Primary Completion Date

November 30, 2029

Study Completion Date

November 30, 2029

Conditions

Bladder Cancer

Interventions

DRUG

FE 999326

75 mL FE 999326 (3 x 10\^11 vp/mL) of sterile suspension instilled once every 3 months into the bladder via a urinary catheter

Trial Locations (24)

Ferring Investigational Site, Nagakute-shi

Ferring Investigational Site, Nagoya

Ferring Investigational Site, Narita-shi

Ferring Investigational Site, Matsuyama

Ferring Investigational Site, Fukuoka

Ferring Investigational Site, Hiroshima

Ferring Investigational Site, Hakodate-shi

Ferring Investigational Site, Sapporo

Ferring Investigational Site, Hitachi-shi

Ferring Investigational Site, Tsukuba

Ferring Investigational Site, Kawasaki-shi

Ferring Investigational Site, Yokohama

Ferring Investigational Site, Nankoku-shi

Ferring Investigational Site, Tsu

Ferring Investigational Site, Sendai

Ferring Investigational Site, Matsumoto-shi

Ferring Investigational Site, Kashihara-shi

Ferring Investigational Site, Okayama

Ferring Investigational Site, Takatsuki-shi

Ferring Investigational Site, Bunkyo-ku

Ferring Investigational Site, Minato-ku

Ferring Investigational Site, Mitaka-shi

Ferring Investigational Site, Toyama

Ferring Investigational Site, Wakayama